At week 72, reduction in body weight greater with tirzepatide compared with placebo
TUESDAY, June 7, 2022 (HealthDay News) — For individuals with obesity, tirzepatide is associated with lasting weight loss, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
Ania M. Jastreboff, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 3 trial involving 2,539 adults with a body mass index of 30 kg/m² or more or 27 kg/m² or more and at least one weight-related complication, excluding diabetes. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks in a 1:1:1:1 ratio.
The researchers found that the mean percentage change in weight was −15.0, −19.5, and −20.9 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and −3.1 percent with placebo. The percentages of participants with a weight reduction of 5 percent or more were 85, 89, and 91 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and 35 percent with placebo; a reduction in body weight of 20 percent or more occurred in 50 and 57 percent of participants in the 10- and 15-mg tirzepatide groups, respectively, and in 3 percent of those in the placebo group. In all prespecified cardiometabolic measures, there were improvements observed with tirzepatide.
“Obesity should be treated like any other chronic disease — with effective and safe approaches that target underlying disease mechanisms, and these results underscore that tirzepatide may be doing just that,” Jastreboff said in a statement.
Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
2018 to 2025 Saw Sharp Rise in Postpartum GLP-1 Receptor Agonist Use
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria